Trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov recruiting set. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Hong Kong phase 3 trial that randomized patients with residual plasma EBV DNA after radiotherapy to adjuvant chemotherapy versus observation; the published result (Chan et al., JCO 2018, PMID 29989858) showed no RFS improvement (5-year RFS 49.3% vs 54.7%; HR 1.09, P=0.75).
Chinese University of Hong Kong
Registration record for the Hong Kong prospective plasma EBV DNA NPC screening program published as Chan et al., NEJM 2017 (PMID 28792880; 20,174 analyzed participants).
Chinese University of Hong Kong
Ongoing EBV DNA-integral randomized phase II/III trial (NRG-HN001): post-chemoradiation plasma EBV DNA is used to assign adjuvant therapy. Enrollment 924. A peer-reviewed primary efficacy results paper was not identified as of 13 Nov 2026.
NRG Oncology
Completed phase 3 DART trial (n=228) of de-escalated adjuvant RT plus docetaxel versus standard adjuvant RT in HPV-associated OPSCC. ctHPVDNA MRD was not used to assign treatment; a 140-patient secondary analysis is PMID 40402484.
Mayo Clinic
Recruiting phase 2 trial (ReACT) of risk-adapted therapy in HPV-positive oropharyngeal cancer using a circulating tumor HPV DNA profile. No primary efficacy paper was identified.
Jonathan Schoenfeld, MD, MPH
Recruiting phase 2 trial using ctDNA testing to decide when to start routine treatment in people with HPV-associated malignancies (planned n=30). Brief title verified via ClinicalTrials.gov API v2 on 13 Nov 2026.
Memorial Sloan Kettering Cancer Center
Phase 2 trial whose registry primary outcome is ctDNA clearance with AZD2936 compared with observation in locoregionally advanced head and neck squamous cell carcinoma that remains MRD-positive after definitive treatment. ClinicalTrials.gov lists the study as recruiting.
University Health Network, Toronto
Recruiting phase 2 trial of de-escalated adjuvant and definitive radiotherapy informed by DART 2.0 circulating tumor HPV DNA, planned enrollment 455. Follow-on to the original DART trial (NCT02908477), in which ctDNA was a secondary correlative rather than the randomization factor.
Mayo Clinic
Recruiting phase 2 trial modulating therapy for locally advanced nasopharyngeal carcinoma based on plasma EBV DNA level after induction chemotherapy (planned n=198).
Fudan University
Recruiting phase 2 trial of adaptive de-intensified radiotherapy guided by circulating tumor DNA in HPV-associated oropharyngeal cancer (planned n=45).
Ohio State University Comprehensive Cancer Center
Recruiting phase 2 trial using circulating tumor DNA to risk-adapt postoperative therapy for HPV-associated oropharyngeal cancer (planned n=50).
Zachary Zumsteg
Interventional study in which people with undetectable postoperative circulating tumor HPV DNA and four or fewer nodes are assigned to observation without further adjuvant treatment. The registry lists the phase as not applicable and the primary outcome as disease-free survival. ClinicalTrials.gov lists the study as recruiting.
Indiana University
NCT07932067 is a not-yet-recruiting phase 2 trial at UPMC Hillman (estimated enrollment 140), led by Kevin Contrera, of surgical drain-fluid ctDNA (LymphDetect Head and Neck) to inform adjuvant therapy in intermediate-risk, HPV-negative head and neck cancer, with 2-year locoregional control in SDF-positive intermediate-risk patients as the primary endpoint. The registry site is UPMC, not Cleveland Clinic.
Kevin Contrera